APTOTrials•globenewswire•
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
Sentiment:Positive (65)
Summary
• Safety Review Committee endorses escalation to 160 mg TUS dosing; no dose-limiting toxicities to date
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 6, 2025 by globenewswire